Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

Found (97) clinical trials

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

Phase

4.71 miles

Learn More »

KRT-232 in Subjects With PMF Post-PV MF or Post-ET MF Who Have Failed a JAK Inhibitor

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study is a global, open-label Phase 2 study to …

Phase

4.71 miles

Learn More »

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Double blind placebo-controlled study. The subjects will receive medication during 4 months.

Phase

4.71 miles

Learn More »

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

This is a two-part study, interventional Phase II, single-arm, multicenter, open-label study to investigate the efficacy and safety of a combination regimen of eltrombopag and cyclosporine in patients with severe aplastic anemia (SAA) as first line therapy and an extension with up to 60-months follow-up. All patients will receive eltrombopag …

Phase

4.71 miles

Learn More »

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Pediatric Participants Assessed to be at Imminent Risk for Suicide

This study will enroll participants with major depressive disorder (MDD) presenting with suicidal ideation who are assessed to be at imminent risk for suicide. The study will be conducted in 4 phases: a screening evaluation performed within 48 hours prior to Day 1 intranasal dose; a 25-day double-blind treatment phase …

Phase

4.71 miles

Learn More »

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin. The purpose of this study is to evaluate the effect of ambrisentan on portal pressure and renal function in patients with advanced …

Phase

4.71 miles

Learn More »

Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

Bladder cancer is the fourth reason of neoplasia in our environment, there are 25 new cases diagnosed per 100,000 inhabitants each year. To decrease the recurrence there are two standardized treatments: Mitomycin as chemotherapy drug and BCG *Bacile Calmette-Gurin" as immunotherapy drug. BCG Moreau strain is not authorized by AEMPS, …

Phase

4.71 miles

Learn More »

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Chemotherapy-nave patients high-intermediate TMB (TMB10 mutations/MB) and with locally advanced or metastatic non-squamous non-small cell lung cancer patients will be selected. Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin (bevacizumab) administered by IV infusion every 21 days (+/- 3 days). The treatment will start within 1-5 days …

Phase

4.71 miles

Learn More »

NADIM II: Neo-Adjuvant Immunotherapy

This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. Patients randomised to the experimental arm will receive Nivolumab 360mg + Paclitaxel 200mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/- 3 days) as neoadjuvant treatment followed by surgery and 1 year of adjuvant treatment with Nivolumab …

Phase

4.71 miles

Learn More »

A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP

This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earlier use of eltrombopag after ITP diagnosis, will allow a larger proportion of subjects to …

Phase

4.71 miles

Learn More »